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Introduction

Abstract: Cell-penetrating peptides (CPPs) have long
held great promise for the manipulation of living cells
for therapeutic and research purposes. They allow a wide
array of biomolecules from large, oligomeric proteins to
nucleic acids and small molecules to rapidly and efficiently traverse cytoplasmic membranes. With few exceptions, if a molecule can be associated with a CPP, it can
be delivered into a cell. However, a growing realization in
the field is that CPP-cargo fusions largely remain trapped
in endosomes and are eventually targeted for degradation or recycling rather than released into the cytoplasm
or trafficked to a desired subcellular destination. This
‘endosomal escape problem’ has confounded efforts to
develop CPP-based delivery methods for drugs, enzymes,
plasmids, etc. This review provides a brief history of CPP
research and discusses current issues in the field with
a primary focus on the endosomal escape problem, for
which several promising potential solutions have been
developed. Are we on the verge of developing technologies to deliver therapeutics such as siRNA, CRISPR/Cas
complexes and others that are currently failing because
of an inability to get into cells, or are we just chasing after
another promising but unworkable technology? We make
the case for optimism.

Nearly 30 years ago, HIV researchers Frankel and Green
(1, 2) independently stumbled upon a phenomenon that
ultimately gave rise to a potentially transformative technology: the HIV protein transactivator of transcription (TAT)
could readily pass through the plasma membrane of uninfected mammalian cells. Further, and most importantly,
TAT retained its normal functionality and subcellular
localization post-entry as it readily entered the nucleus
and promoted gene transcription. This surprising ability
to traverse the cellular membrane was later mapped to a
stretch of 12 basic amino acids and this penetrative property could be conferred onto other proteins to which that
sequence was fused (3, 4). A new area of intense scientific
research was thus born: the delivery of bioactive molecules into mammalian cells via direct penetration of the
plasma membrane.
Since Frankel’s and Green’s discoveries, a large
number of peptides that are rapidly internalized and
enable transport of macromolecular cargos into mammalian cells in vitro and in vivo have been discovered or
designed. These peptides came to be known as cell-penetrating peptides (CPPs, also frequently referred to as
protein transduction domains, or PTDs). The term CPP
now refers to a broad grouping of non-homologous short
peptides, the majority of which are hydrophilic and cationic in nature, though amphiphilic, anionic and hydrophobic CPPs have been reported. A database of more than
1600 CPPs is described by Agrawal et al. (5). Their unifying property is the ability to penetrate the plasma membrane for delivery of cargo into cells, from peptides and
proteins, both small and large, to various nucleic acids,
including DNA, RNA, small interfering RNAs (siRNAs) and
peptide-nucleic acids (PNAs) (6–9).
Thirty years later, CPP-based technologies have
largely failed. Frankel and Pabo (1) first reported that
cellular entry of TAT was likely via an endosomal-independent mechanism as introduction of the endosomalblocking agent chloroquine enhanced TAT uptake into
cells. However, much of the subsequent data supporting
spontaneous membrane translocation were found to be
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the result of experimental artifacts. It was soon realized
that majority of CPPs became trapped in endosomes following delivery into cells and, as a result, any associated
cargo became trapped as well (10, 11). It is likely the case
that, owing to endosomal entrapment, the vast majority
of CPP cargos are eventually targeted to either the lysosome for degradation or back to the plasma membrane for
recycling and subsequent ejection from the cell. We have
dubbed this the ‘endosomal escape problem’.
In spite of setbacks, CPPs still have significant therapeutic and investigative potential. Currently, more than 25
CPP clinical trials are underway, including a Phase III (12,
13). To successfully transition CPP-based technology into
therapeutic delivery systems, several considerations need
to be made. This review focuses on fundamental questions
and the challenges faced by the field in this endeavor:
How do CPPs get into the cell? Once inside, how is cargo
released from the endosome into the cytosol? How do we
ensure biological activity and correct subcellular localization of cargo following endosomal release? And finally,
how can we ensure specificity in cellular targeting?

Breaking in: mechanisms of cellular
entry
Currently, the field recognizes endocytosis to be the
primary mode of CPP cellular entry and subsequent endosomal escape, the rate-limiting step for the effectiveness
of CPPs to deliver cargo into living cells. However, there
is still much controversy on how CPPs enter cells. In this
section of the review, we will provide a brief history of
30 years of mechanistic insight on CPP cellular entry with
a primary focus on endocytosis.

A brief glance at endocytic pathways
Endocytosis is a broad term encompassing a variety of
pathways utilized by the cell to bring outside molecules
in for a multitude of purposes – receptor and lipid recycling, inhibition of signal transduction, uptake of solutes/
nutrients and destruction of foreign/unwanted materials.
The unifying property of endocytic pathways is, simply
put, engagement of the plasma membrane for the formation of an intracellular membrane-bound organelle which
will then transport the molecules to some destination
within the cell. It is a tightly coordinated, energy-dependent process requiring extensive cellular adaptors and
cytoskeletal rearrangements. As illustrated in Figure 1,
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Figure 1: An overview of endocytosis.
Endosome formation may be receptor (clathrin/caveolin) or
non-receptor mediated (macropinocytosis). Following invagination (clathrin/cavaeolin) or evagination (macropinocytosis) of the
plasma membrane, an early endosome is formed (1). As the endosome travels into the cell, it transitions to an early endosome and
becomes increasingly acidified by pumping in cytosolic hydrogen
ions into the vesicular lumen (2). As the early endosome matures, it
begins to sort cargo by the formation of multiple smaller intraluminal vesicles (ILVs) (3). Some of these vesicles may re-fuse with the
endosomal membrane and deliver contents directly into the cytosol,
called ‘backfusion’ while others will be destined for either the lysosome (4) or the trans-Golgi network (TGN) (5). Cargo delivered to the
lysosome will be degraded while cargo delivered to the TGN will be
recycled back to the plasma membrane. Some receptors can bypass
the TGN and be directly recycled back to the plasma membrane from
the early endosome (6).

following organelle formation, an endocytic vesicle
undergoes a pH-dependent maturation process as it transitions from the early sorting endosome (pH ~6–6.5) into
the late endosome or multivesicular body (MVB; pH ~5).
The acidification process is dependent on ionic gradients,
requiring calcium, sodium and potassium efflux as well
as hydrogen and chloride influx. An endosome has three
potential fates – it may be targeted to the lysosome from
the MVB for destruction of its intraluminal contents or its
contents may be recycled back to the plasma membrane
either directly from the sorting endosome or after routing
from the MVB to the trans-Golgi network. Alternatively,
some endosomal contents such as nutrients are needed
by the cell and, thus, must be released into the cytosol.
This latter process is mediated by the formation of intraluminal vesicles (ILVs) inside the endosome, essentially the
formation of an exosome within the endosome. The ILV
then undergoes a process known as ‘backfusion’ where it
fuses with the endosomal membrane and its contents are
released into the cytosol.
Endocytosis can further be broken down into phagocytosis and pinocytosis depending on whether entry is
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fluid phase or not. We will limit our discussion to pinocytic pathways most commonly engaged by CPPs – macropinocytosis, clathrin-dependent and caveolin-dependent
endocytosis and lipid-raft endocytosis. A full description
of these pathways is outside the scope of this review;
however, a brief description of these pathways is provided
below:
1. Macropinocytosis is defined as a receptor-independent and coat-independent process. First described by
Warren Lewis in 1931, this is a form of cellular ‘pino’
(drinking) ‘cytosis’ (14). Macropinocytosis is classically thought to be a non-specific mechanism to bring
solutes/nutrients into the cell via large endocytic vesicles. However, more recent studies point to a need for
stimulation at the plasma membrane via the presence
of extracellular growth factors [reviewed in Ref. (15)].
Further, different cell types may utilize this process in
different ways given their particular needs. For example, some cells use this process to obtain nutrients or
to recycle portions of their membranes while immune
cells utilize macropinocytosis for the regulation of
antigen presentation.
2. Clathrin-dependent endocytosis is a receptor-driven
process that results in the formation of a ‘coated’ vesicle. The trimeric coat protein, clathrin, for which this
pathway is defined, was the first coat protein to be isolated from cellular membrane-bound vesicles in 1976
by Pearse (16). During endocytosis, three-footed triskelion subunits assemble via adaptor proteins at cholesterol-deficient regions of the plasma membrane,
forming into a lattice work to create a highly ordered
‘caged’ structure which is internalized. This pathway
is considered ubiquitous across all cell types and is
utilized in a variety of ways; transferrins, low-density
lipoproteins, hormones and neurotransmitters (during reuptake) are a few examples of molecules taken
up by this pathway.
3. Caveolin-mediated entry shares both similarities and
distinctions from clathrin-mediated entry. Caveolins
are also coat proteins that form tight associations
with cholesterol present in the plasma membrane.
Unlike the trimeric clathrins, following recruitment to
the plasma membrane, caveolins form a distinct ‘U’
shape, with both N- and C-termini pointing toward
the cytoplasm. The resulting invaginations resemble
cave-like structures called caveolae, for which they
were originally named (17). Not surprisingly, caveolins are found localized to cholesterol-rich lipid rafts.
Many growth factors utilize this pathway, as do some
pathogens. Further, caveolin-dependent endocytosis
is important in transendothelial transport. Unlike the
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more ubiquitous mechanism of clathrin-dependent
endocytosis, caveolae formation is impacted by many
cellular factors such as cell type as well as cell cycle
progression. Further, some cells express caveolins at
low levels or not at all.
4. Lipid raft endocytosis is a non-receptor-mediated,
concentration-dependent form of endocytosis occurring at cholesterol-enriched lipid rafts in the plasma
membrane but does not rely on caveolin coat formation. In this form of endocytosis, glycosylphosphatidylinositol-anchored proteins (GPI-AP) group
into distinct microdomains, invaginate and form
GPI-enriched intracellular vesicles. This pathway is
primarily used as a constitutive means of bringing
in extracellular fluids through lipid-raft-mediated
pathways based in membrane-molecule interactions
and has been described for SV40-virions, vitamins,
GPI-binding proteins, MHC-class I, IL-2 and IgE. Even
though these pathways show significant variability
for the requirement of local mediators and in cargo
fate (recycling, degradation, intracellular release),
they share commonalities in that they are receptormediated and proceed via an absorptive fluid-phase
mechanism [reviewed in Ref. (18)].

Breaking in via endocytosis:
the case and conundrum
Individual CPPs may engage one or more of the forms of
pinocytosis defined above. With regard to TAT, different
groups have reported cellular uptake by all of these endocytic mechanisms (19–25). Further, some CPPs such as
the well-studied arginine-rich, 16-residue peptide corresponding to the third helix of the Drosophila melanogaster
transcription factor Antennapedia homeodomain (Antp;
penetratin) may enter via direct penetration (26). The
debate is ongoing; CPP entry mechanism(s) is a heavily
explored area with minimal consensus. Much of this likely
owes to differences in laboratories, cell types, CPP constructs and experimental conditions.
Frankel and Pabo (1) demonstrated in their seminal
paper that lysotrophic agents enhanced instead of blocking full-length TAT uptake into cells. This gave rise to the
direct penetrance hypothesis that was rapidly embraced
by many in the field. Three years later, Mann and Frankel
(27) provided data that full-length TAT likely entered
via an undefined absorptive-phase endocytic pathway.
Namely, they found that uptake was significantly reduced
when performed at 4°C (energy independent) compared
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with 37°C. Interestingly, this was a cell-dependent effect
as cervical cancer-derived cells (HeLa) showed a striking
difference in energy-dependent uptake while temperature
reduction had a notably smaller, though similar, impact
on a T cell-derived cell line (27). This was the first illustration of a cell-type effect on TAT uptake and these findings
hinted at complexities with which we are still coming to
grips, including the importance of cell-specific differences
in CPP uptake.
The 1990s saw a flurry of reports of direct penetrance
by CPPs. However, many of these observations were later
found to be artifactual (10). In particular, Lundberg et al.
(10) demonstrated that intracellular redistribution and
dispersed cytoplasmic and nuclear distribution of CPPs
resulted from cellular fixation, whereas live cell imaging
experiments indicated a punctate (likely endosomal) distribution. More recent work utilizing live cell imaging has
shown evidence for the potential of non-endocytic uptake
of some CPP constructs, but these data are not without
constraints on the concentration of the CPP and nature of
the cargo (19, 28).
By the onset of the 21st century, over a decade from
the initial reports of TAT’s ability to traverse the plasma
membrane, multiple conflicting reports were published in
support of one endocytic pathway over another engaged
by TAT as well as those of other newly discovered CPPs, as

outlined in Table 1. In 2007, Duchardt et al. (19) designed
a series of experiments to clarify contradictory data on
the use of endocytic pathways by CPPs that plagued the
field. They studied concentration-dependent uptake
mechanisms of three well-characterized cationic CPPs
(penetratin, TAT and R9) employing specific endosomal
pathway inhibitors and tracers. It was demonstrated that
all three CPPs engaged multiple forms of endocytosis
(clathrin-dependent, caveolin-dependent and macropinocytosis) and that the concentration of the CPP played
a role in determining the endocytic pathway that was
used. While these data are seemingly at odds with previous work, many proteins, receptors and viruses make
use of all of these forms of endocytosis. Further, while all
of these pathways exhibit specificity, there exists a large
degree of functional redundancy and crosstalk among
them.
Ten years later much remains unresolved concerning
how CPPs enter a cell. Even though endocytosis gained the
limelight as the primary means of entry, direct penetrance
still remains a distinct possibility and an active area of
interest in the field. Determinants dictating CPP utilization of one endocytic pathway over another, or bypassing
the endosome entirely, are thought to be highly contextual
and dependent on the nature of the CPP, concentration,
receptor availability, media conditions and cell type. A

Table 1: Experimental evidence for the use of different endocytic pathways by TAT in different cell lines.
Endocytic pathway

Cell line

Endocytic pathway inhibitorsa/tracers

Methodology

Macropinocytosis

Tex.Ioxp.EG (T-cells)
Cos-7 (fibroblasts)
CHO
K562 (lymphoblasts)
HeLa

Flow cytometry, live cell imaging (23)
Live cell imaging (23)
Immunohistochemistry (23)
Flow cytometry (29)
Flow cytometry (30)
Flow cytometry, live cell imaging (19)

Cos-1 (fibroblasts)

β-Cyclodextrin; nystatin; EIPA; cytochalasin D (23)
EIPA; cytochalasin D/RFP-labeled caveolin (23)
Dyamin knockdown/transferrin (23)
ATP-depletion; EIPA (29)
Chlorpromazine; potassium reduction/transferrin (30)
Chlorpromazine (effective at high concentrations of TAT
– 40 μm); EIPA; MβCD (19)
4°C Incubation; chlorpromazine; filipin; Eps15, dynamin
and intersectin dominant-negative mutants (25)
Potassium reduction, nystatin/transferrin (30)
4°C Incubation/cholera toxin, transferrin, CFP-labeled
caveolin (20)
Cytochalasin D, MβCD, 4°C incubation/transferrin,
EEA-1, cholera toxin (24)
Cytochalasin D, MβCD, 4°C incubation/caveloin-1 (24)

Lipid raft

Jurkat T-cells

Cytochalasin D, MβCD, 4°C incubation (24)

Undefined

PBM-MOs
HUVEC

ATP-depletion, 4°C incubation (30)
ATP-depletion, 4°C incubation (30)

Clathrin-dependent

Jurkat T-cells
CHO
Caveolin-dependent HeLa

Radioactivity labeling,
immunohistochemistry (25)
Flow cytometry (30)
Live cell imaging (20)
Live cell imaging,
immunohistochemistry, reporter
assays, flow cytometry (24)
Flow cytometry,
immunohistochemistry (24)
Flow cytometry,
immunohistochemistry (24)
Flow cytometry (30)
Flow cytometry (30)

a
Inhibitors: macropinocytosis – EIPA; clathrin – cytochalasin D, chlorpromazine, potassium reduction; caveolin – flipin, β-cyclodextrin,
nystatin; lipid raft-β-cyclodextrin, nystatin, potassium reduction.
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better understanding of the factors influencing one form
of uptake over another in different target cells and tissues
will be paramount in optimizing targeting, uptake and
endosomal escape strategies to develop CPPs for effective
cargo delivery in vivo and in vitro.

A receptor for CPPs?
Regardless if cellular entry is direct or endosomal, the
CPP must initially come into contact with the plasma
membrane to facilitate uptake. Thus, requirements for
cellular entry are a primary question in the field. Currently, CPP-membrane interaction is thought to be governed by either non-specific electrostatic interactions or
via ligand-receptor binding. Given that TAT, the prototypical CPP, is derived from a HIV protein, much of the
work in this arena has been based on HIV research and
has utilized either TAT or TAT-homologous arginine-rich
CPPs.
Early work on HIV entry mechanisms revealed that
full-length TAT could bind, among other molecules,
ubiquitously expressed cellular proteoglycans (namely
heparan sulfate proteoglycans, or HSPGs), integrins and
chemokine (C-X-C motif) receptor 4 (CXCR4), though in the
latter case it serves as an antagonist (31–36). All of these
molecules readily activate endocytic pathways in both
clathrin-dependent and -independent mechanisms. In
particular, binding to HSPGs and integrins was mapped to
the basic domain of TAT, which also confers its cell-penetrating properties (31). In 1993, Vogel et al. (34) reported
that while the basic domain of TAT could readily bind
integrin αvβ5, antibodies blocking this interaction had no
effect on TAT uptake into cells. Since these observations,
HSPGs have received prominent attention as potential TAT
receptors (29, 30, 33, 37–39).
Interaction between TAT’s basic domain (its CPP
sequence) and heparan sulfates (HSs) was originally elucidated by Rusnati et al. (40). These observations were
expanded upon in 2001 by Tyagi et al. (33) who provided
evidence for the need for cell surface proteoglycans
for cellular internalization of TAT constructs, as cells
defective in glycosaminoglycan (GAG) synthesis showed
reduced TAT uptake. Mounting evidence for the roles
of HSPGs in uptake and endocytosis of arginine-rich
CPPs such as TAT have provided a new framework for
the study of receptor-mediated entry of CPPs (29, 30, 33,
37–40). With respect to cationic CPPs, interactions with
negatively charged GAGs comprising HSPGs are thought
to concentrate these CPPs at the plasma membrane to
facilitate endosomal uptake.
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Expanding upon the HSPG-CPP interaction hypothesis, Letoha et al. (29) in 2010 and Kawaguchi et al. (37)
in 2016 identified the ubiquitous HSPG syndecan 4 as a
potential receptor for the classical arginine-rich CPPs.
Letoha et al. (29) reported that syndecan 4 enhanced the
uptake of TAT, penetratin and the bioengineered octoarginine peptide R8 via an energy-dependent endocytic
mechanism they attributed to macropinocytosis. This is
not surprising as syndecan 4 is known to activate multiple
downstream small GTPases involved in different endocytic
pathways including macropinocytosis, clathrin-dependent and caveolin-dependent endocytosis as well as lipid
raft-dependent endocytosis (41, 42). A major limitation to
this work is the use of a cell-based overexpression system
in lymphoblasts, which normally do not express syndecans. There is some doubt as to whether a cell that does
not normally express this molecule will recreate normal
syndecan-mediated cellular uptake pathways following
transfection.
Kawaguchi et al. (37) later performed a screen for
binding partners of R8 in HeLa cells. They identified 17
potential R8 binding partners, seven of which are proteoglycans and two of which are core components of the
extracellular matrix (ECM). They confirmed that syndecan 4 facilitated cellular entry of R8 in a concentrationdependent manner, as siRNA-mediated knockdown of
syndecan 4 impacted uptake at a low concentration (1 μm),
but only had little effect at a high concentration (10 μm)
(37). In contrast to previous observations, R8 appeared
to predominantly utilize a clathrin-dependent endocytic
pathway instead of micropinocytosis though this may be a
by-product of experimental conditions (22).
The other recently identified candidate receptor,
CXCR4, is highly expressed on migratory cells such as
immune and cancerous cells. CXCR4 was originally
identified as a key receptor for HIV type X4 and works
in concert with co-receptor CD4 and cell-surface HSPGs
to facilitate viral entry into target cells (35, 36). In 2012,
Tanaka et al. (43) provided evidence for the use of CXCR4
followed by subsequent macropinocytosis by the arginine-rich CPP R12. In support of CXCR4 and syndecan
4 serving as receptors for arginine-rich CPPs, CXCR4 is
normally complexed with syndecan 4 and that association promotes binding of its natural ligand, stromal cellderived factor 1 (SDF-1) (44). At odds with this, however,
Tanaka et al. found that CXCR4 facilitated uptake of
R12 but not the other arginine-rich CPPs, TAT or R8, the
latter being the proposed receptor of syndecan 4 (37,
43). The failure of TAT to bind CXCR4 likely owes to the
fact that binding to CXCR4 has been mapped to TAT’s
central ‘chemokine-like’ domain though direct analysis
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of its basic domain binding to CXCR4 has not been performed to our knowledge. Finally, CXCR4 is found in low
abundance in normal, non-migratory, healthy cells and
tissues; so, while CXCR4 may facilitate the uptake of at
least one CPP, R12, as noted by the authors, it is likely not
the sole receptor.
Identifying receptors for different CPPs will be paramount in untangling mechanisms of entry and may lead to
the development of more efficient cargo-delivering CPPs.
However, if CPPs can readily utilize more ubiquitously
expressed molecules such as HSPGs, this may reduce the
therapeutic value without effective targeting strategies.
Further, failure to control endocytic pathway engagement
means a variety of fates may await any given molecule
every time it is introduced.

Busting out: escape from
the endosome
The field has increasingly recognized that the principal
roadblock to the development of therapeutics is cargo
entrapment in the endocytic pathway (13, 45). Almost
all described CPP technologies are reliant on covalent
crosslinking or non-specific hydrophobic interactions
(46). In our opinion, it is here that CPPs currently fail as
a workable technology. If cellular entry is receptor mediated, it could well be that the high affinity of the CPP for
its receptor is in part due to low off rates and hence trapping of its linked cargo in the endosomes may essentially
be a kinetic problem. In this section, we focus on some of
the more promising approaches that have been developed
to facilitate escape from the endosome.

Promising tricks for facilitating endosomal
escape
The most promising ‘tricks’ to overcome entrapment
include the use of endosomolytic agents, reversible covalent binding and reversible high-affinity non-covalent
binding. The Pellois group has developed an endosomolytic agent to promote release of cargo via endosomal
leakage. Their dimerized disulfide-linked TAT (dfTAT) can
destabilize endosomes for the delivery of co-incubated
cargo (47, 48). This methodology is particularly attractive as it allows for introduction of cargo, even multiple
cargos, without direct interaction with TAT. Further, utilization of disulfide bonds should enhance stability for
systemic delivery.

Another promising method is the use of endosomal
disruption agents based on antimicrobial peptides (49).
Using a CPP that also incorporated two membrane-disrupting antimicrobial peptides, investigators were able
to overcome endosomal entrapment, hypothesizing that
membrane disruption occurred during vesicular trafficking as the CPP reached the ‘critical membrane disrupting
concentration’, thus effecting endosomal escape. A follow-on study demonstrated the utility of Salomone et al.’s
(50) design as a transfection agent with ionically linked
nucleic acids and CPPs. Other similar efforts to selectively
disrupt endosomal membranes include engineering of
‘endosomal escape domains’ (EEDs) (51) and use of pHsensitive peptides (23).
Several groups have developed novel reversible
strategies that may have advantages over endosomolytic
agents in toxicity, specificity and simplicity. Among the
reversible strategies, the most common is the use of thiol
coupling. The reducing environment of both the endosome and the cytoplasm should be an effective means to
reduce disulfides and uncouple cargo from CPP. Further,
as with the dfTAT model, the use of thiol coupling should
provide stability and protect the cargo/CPP during systemic delivery. Another approach described by Rossi
et al. (52) utilizes an interesting photocleavable linkage
to deliver cleaved peptides to the cytosol. While this may
overcome entrapment, this strategy is seemingly impractical for many applications as it would be difficult to get
light to many places within patients. The potential of this
strategy as a research tool, however, may be high.
Models that utilize non-covalent CPP-cargo linkages
can overcome problems associated with covalently bound
cargo. Our group has recently described a novel CPP-adaptor method that exploits normal ionic gradients to free
cargo following endosomal entry (53). We associated CPPs
with their cargos via a reversible coupling between a CPPcontaining calmodulin and cargo that contains a calmodulin binding site (CBS). Our initial findings, described in
Ref. (53), showed that TAT-fused calmodulin (TAT-CaM)
bound CBS-containing cargos with nanomolar affinity in
the presence of calcium but not at all in its absence. In that
study, three model cargos and three distinct cell lines were
used, demonstrating general, efficient and rapid delivery
of cargo to the cytoplasm at a much lower dose (1 μm)
than necessary using other means. Further, when calcium
was removed from bound TAT-CaM-cargo complexes, very
rapid dissociation ensued. As illustrated in Figure 2, the
high calcium concentrations of the extracellular environment ensures high-affinity CPP-cargo binding. Following
entry into the cell, the extracellular calcium is rapidly lost
as the endosome becomes increasingly acidified (54). We
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Figure 2: Proposed model for TAT:CaM-mediated intracellular delivery of CBS:CARGO.
TAT fused with a calmodulin (TAT:CaM) will readily associate with
cargo containing a calmodulin-binding site (CBS:CARGO) in the
extracellular environment owing to high levels of calcium (1). Following binding of TAT:CaM to a receptor, an endosome will form
containing the TAT:CaM-CBS:CARGO as well as high levels of extracellular calcium. As the endosome matures, calcium will be pumped
out of the intraluminal space while hydrogen ions are brought in (2).
This shift in calcium concentrations within the endosome will cause
the CBS:CARGO to disassociate from TAT:CaM, allowing for release
of the cargo into the cytosol, presumably through ILVs, even if
TAT:CaM remains tightly bound to its receptor (3). TAT:CaM itself may
have multiple possible fates following formation of the late endosome. It may be sent to the lysosome for degradation if it retains
its ability to bind its receptor in increasingly acidic conditions (4) or
sent to the TGN (5) for recycling back to the plasma membrane (6).

hypothesize that as calcium levels drop, the CPP adaptor
releases its cargo from the early endosome prior to formation of the more acidic late endosome.
Considerable attention has been given to the design
of new, more efficient, delivery mechanisms. The use of
non-covalent association of CPPs with their cargo is, in
our opinion, a key strategy to enhance bioavailability of
biologically active molecules. By non-covalently coupling
the cargo from the CPP, problems with endosomal entrapment and the potential for a loss of biological activity are
easily surmountable. Finally, these methodologies typically require reduced and more therapeutically feasible
concentrations of protein for the desired effect.

Subcellular localization: targeting freed
cargo to specific intracellular compartments
Once cargo has been delivered into the cell and successfully escaped the endosome, how does the cargo get targeted to a particular location within the cell? Much of
our understating of subcellular localization of proteins is
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derived from the basic knowledge of signal peptides that
facilitate localization of proteins to intracellular compartments. Within the endomembrane system, such delivery is
achieved through sorting of localization signals and subsequent vesicular-mediated targeted delivery. However,
many subcellular compartments can directly import cytosolic proteins provided they contain a specific targeting
sequence. Such examples include mitochondrial import;
receptor-mediated nuclear import export; cotranslational
entry into the ER and import of cytosolic proteins, such
as catalase, into peroxisomes post-budding off the ER
membrane.
Protein replacement therapy aims to deliver a fully
functional protein to replace one that has been mutated,
lost or is underexpressed. Under ideal circumstances, a
protein is successfully delivered into the cell, freed from
the endosome and behaves exactly like a wild-type endogenous protein. In the past decade, several groups have
been successful in this endeavor. A group from the Hebrew
University-Hadassah Medical School, led by LorberboumGalski et al. (55), has developed and successfully delivered
functional proteins to the mitochondria in vitro to restore
defects in the electron-transport chain and acetyl Co-A
production (56) associated with life-threatening mitochondrial diseases. Other groups have also demonstrated
the ability to deliver functional copies of proteins into
cells to alleviate dysfunctional proteins associated with
mitochondrial and lysosomal diseases. For example, in
2012, Honda et al. (57) were able to deliver functional subunits of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex to the cytosol to restore its
activity ex vivo in neutrophils from patients suffering from
chronic granulomatous disease (CGD), a disease characterized by improper reactive oxygen species (ROS) production resulting from defective NADPH complexes. While
conceptually simple, these approaches are not without
significant consideration to ensure the protein will behave
as it should within the cell. The protein must be produced
in highly purified, properly folded conformation, have its
native subcellular localization signal accessible to subcellular import machinery (in the case of non-cytosolic
proteins), show normal dynamics of stability and activity,
be expressed at normal endogenous levels, engage with
binding partners and, in many cases, be able to undergo
post-translational modification.
Delivery of therapeutic molecules into the cell often
requires artificial means for intracellular localization of
the molecule to the compartment of interest. The predominant approach for targeting CPP-bound cargo calls
for the fusion of canonical signal sequences to cargo proteins, or even to the CPP tag itself [reviewed in Ref. (58)].
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Using this methodology, cargos have been delivered to the
nucleus (59, 60), the nucleolus (61), the lysosome (62),
the peroxisome (59), the mitochondria (59, 63, 64) and
the endoplasmic reticulum (59, 65), to name a few. Drawbacks to this approach include decreased uptake of tagged
CPPs (65) and potential endosomal entrapment en route
to the intended compartment. The underlying mechanism
via which some of these CPP-cargo complexes gain entry
into specific subcellular compartments is less well understood. Within the endomembrane system, it is tempting
to speculate that one might be able to exploit endosomal
entry for cargo targeting though ensuring proper sorting
within the late endosome may present challenges.

Targeting CPPs to specific cell types
The specific delivery of cargo to a particular target cell
or tissue via CPP-mediated methods remains the Holy
Grail of pharmacological work in this field [reviewed in
Ref. (66)]. The central problem is that of specificity: given
that CPP uptake is thought to occur via a general mechanism with a ubiquitous cellular receptor such as HSPGs
or membrane apparatus, it is extremely facile to deliver
CPP-tagged cargo proteins systemically. The technical
challenge, albeit not insurmountable, is to deliver them to
a particular site, tissue or organ system.
Initial work in this area centered on localized injection of CPP-tagged cargo proteins. While these approaches
yield the desired effect of delivery of CPP cargo directly
to tumor cells, they are only effective for solid, localized
tumors or easily isolated or discovered target regions.
Other strategies involve exploiting the biochemical
nature of target cells/tissues. So-called activatable cellpenetrating peptides (ACPPs) pair technical innovation
with an improved working knowledge of the affected cellular biochemistry and have been successful with some
degree of target specificity by several groups [reviewed
in Ref. (67)]. These ACPPs are activatable in a stimulusdependent manner and are caged or masked until they are
in the vicinity of their target. This methodology employs an
anionic inhibitor to shield cationic CPPs until they are near
cells or tissues whose extracellular environment contains
a product capable of cleaving the anionic inhibitor, thus
freeing the CPP at a target site. This methodology was successfully used in 2004 to target tumor cells by Jiang et al.
(68) who used a proteolytic cleavage site targeted by metalloproteases secreted from tumor cells. These results were
further confirmed in two reports in 2009 by Olson et al.
and Aguilera et al. of the Tsien group (69, 70). However,
due to endosomal entrapment (70) and significant

off-target uptake by other tissues in vivo (71), this technology has developed primarily as a means to target tumors
for imaging purposes, which in and of itself has significant
value.
More recent studies have utilized pH-, photo- and
hydrogen peroxide-sensitive CPP linkers to target desired
tissues. In 2014, Weinstain et al. (72) described a hydrogen
peroxide-sensitive linker that was targeted at lung tissues
following induction of lipopolysaccharides (LPS)-mediated inflammation in a murine model. Given that infection
results in high levels of ROS, the constructs would ideally
only be cleaved in regions undergoing an inflammatory
response (perhaps cleverly harnessing the endosomal
entrapment problem in a good way, withholding cargos
from off-target cell cytoplasms and targeting them for
destruction!). In 2016, Yang et al. (73) successfully delivered siRNA in nanoparticles to tumors by exploiting lower
pH conditions present in those tumors. However, that
cleavage of the linker relied on both low pH conditions
and exposure to near IR light confers substantial accessibility limitations. While these studies, and others, yield
clever and promising targeting mechanisms, they still
lack the degree of specificity that may be needed for widespread therapeutic application as the potential for off-target uptake by healthy cells remains a significant concern.
One means of overcoming off-target effects utilizing
stimulus-dependent methodology is to deliver an ACPP
that can only be cleaved within targeted cells, provided
they contain the product needed for cleavage. This socalled ‘Trojan Horse’ strategy was first employed by
Vocero-Abkani et al. (74) in 1999 when the TAT peptide was
used to deliver procaspase-3 to HIV-infected cells. Here,
the proteolytic site was replaced by the proteolytic site for
HIV-1 protease. Upon uptake of the cargo into HIV-infected
cells, caspase-3 is processed, killing the infected cells (74).
And while this methodology may have significant therapeutic potential, it is certainly limited to specific diseases
and lacks broader applications.
Perhaps most promisingly, recent biopanning strategies have identified a number of short peptides that confer
cell-type-specific delivery of cargo proteins via CPP-mediated transduction. Zahid et al. (75) used this approach to
identify a cardiac-specific peptide, termed cardiac-targeting peptide (CTP), which facilitated cargo uptake specifically to cardiomyocytes following systemic introduction.
More recently, a cancer-specific CPP was designed by Lim
et al. (76). This CPP, called BR2, showed enhanced selectivity and nearly a 70% overall increase in cellular uptake
in cancer cell lines in comparison with normal cells.
When moving from bench to bedside, enhancing specificity and decreasing off-target effects will be
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paramount. Considerable attention needs to be given
to the nature and goal of the treatment and optimization of the CPP construct to serve these purposes. What
has become increasingly clear is that a one-size-fits-all
model will not be useful in this endeavor. As argued
above, CPPs that bind ubiquitously expressed membrane proteins will have little promise as to specificity
without a coincident secondary targeting scheme, such
as a nanoparticle. However, with significant advances in
understanding CPP-cell interactions and the biochemical
nature of afflicted cells of interest, designer therapeutic
CPPs are clearly on the horizon.

Outlook: cause for optimism
CPPs hold the immense promise of rapid, efficient, nontoxic delivery of biomolecules into living cells and thus
represent great hope for development of enabling technologies for delivering therapeutics now stymied by poor cellular entry. They may also confer other advantages such as
fine control of dosing as compared to transfection or other
disruptive delivery method. Technical problems with CPP
delivery, while significant, may soon be solved with rather
simple solutions that dissociate cargo from CPP via spontaneously cleavable or non-covalent linkages, opening
the door to new generations of therapeutics. Prospects
for even further enhanced utility by cell-specific targeting
and increased ease of coupling, etc. may make them even
more profoundly effective.

Highlights
–– CPPs can readily enter a variety of cells utilizing multiple forms of endocytosis and, potentially, via direct
penetrance.
–– CPP-based technologies are one of the most promising means for delivery of a wide variety of cargo (proteins, peptides, DNA, siRNAs) into living cells.
–– Endosomal entrapment of CPP-conjugated cargo is a
limiting factor for the effectiveness of CPPs for protein
delivery.
–– Current approaches to achieve endosomal escape
of CPP-associated cargo are destabilization of
endosomes, the use of cleavable linkers and noncovalent attachments.
–– Biological CPPs likely enter cells via ubiquitous mechanisms; however, designer CPPs are effective at targeting specific cells and tissues.
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